8-K Announcements
6Material company update
Feb 13, 2026·SEC
Material company update
Feb 13, 2026·SEC
Material company update
Jan 27, 2026·SEC
ProPhase Labs, Inc.(PRPH)Earnings, Financials & Key Ratios
PRPH•NASDAQ
$0.14
$6M mkt cap·Price updated May 6, 2026
AboutProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Show more
- Revenue$7M-84.7%
- EBITDA-$32M-114.4%
- Net Income-$53M-218.0%
- EPS (Diluted)-2.61-166.3%
- Gross Margin-2.22%-106.1%
- EBITDA Margin-472.45%-1305.9%
- Operating Margin-570.59%-1071.8%
- Net Margin-788.24%-1984.7%
- ROE-188.11%-533.4%
- ROIC-59.44%-134.2%
- Debt/Equity3.34+794.2%
- Interest Coverage-11.53+32.0%
PRPH Key Insights
ProPhase Labs, Inc. (PRPH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗High debt to equity ratio of 3.3x
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 7.3% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PRPH Price & Volume
ProPhase Labs, Inc. (PRPH) stock price & volume — 10-year historical chart
Loading chart...
PRPH Growth Metrics
ProPhase Labs, Inc. (PRPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-11.15%
5 Years-7.27%
3 Years-55.92%
TTM-91.55%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-50.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-8.61%
Return on Capital
10 Years-19.29%
5 Years-15.09%
3 Years-24.49%
Last Year-75.64%
PRPH Peer Comparison
ProPhase Labs, Inc. (PRPH) competitors in Consumer health and OTC self-care — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 QDEL | 746.18M | 10.96 | -0.66 | -1.89% | -45.57% | -56.31% | 1.46 | |
 CLOV | 1.37B | 2.68 | -15.76 | 40.34% | -2.58% | -17.08% | ||
 BNGO | 13.64M | 1.27 | -0.26 | -7.37% | -92.59% | -56.22% | 0.16 | |
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 FLGT | 443.83M | 14.92 | -7.57 | 13.83% | -18.75% | -5.42% | 0.00 | |
 CERS | 518.96M | 2.59 | -31.59 | 14.35% | -4.41% | -15.18% | 1.49 | |
 TMO | 175.76B | 472.95 | 26.66 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare PRPH vs Peers
ProPhase Labs, Inc. (PRPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PRPH Income Statement
ProPhase Labs, Inc. (PRPH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 21.01M | 9.87M | 13.13M | 9.88M | 14.51M | 79.04M | 122.65M | 44.38M | 6.77M | 1.08M |
| Revenue Growth % | 1.99% | -53.05% | 33.03% | -24.76% | 46.96% | 444.59% | 55.17% | -63.81% | -84.75% | -91.55% |
| Cost of Goods Sold | 10.95M | 7.92M | 8.35M | 7.26M | 9.91M | 46.23M | 51.99M | 28.14M | 6.92M | -984K |
| COGS % of Revenue | 52.1% | 80.26% | 63.58% | 73.52% | 68.27% | 58.49% | 42.39% | 63.41% | 102.22% | - |
| Gross Profit | 10.07M▲ 0% | 1.95M▼ 80.6% | 4.78M▲ 145.4% | 2.62M▼ 45.3% | 4.61M▲ 76.1% | 32.81M▲ 612.4% | 70.65M▲ 115.3% | 16.24M▼ 77.0% | -150K▼ 100.9% | 2.06M▲ 0% |
| Gross Margin % | 47.9% | 19.74% | 36.42% | 26.48% | 31.73% | 41.51% | 57.61% | 36.59% | -2.22% | 191.36% |
| Gross Profit Growth % | -17.34% | -80.65% | 145.43% | -45.3% | 76.14% | 612.42% | 115.32% | -77.02% | -100.92% | - |
| Operating Expenses | 12.72M | 5.94M | 6.42M | 5.85M | 8.58M | 23.01M | 47.06M | 37.85M | 38.48M | 28.95M |
| OpEx % of Revenue | 60.54% | 60.18% | 48.87% | 59.27% | 59.11% | 29.11% | 38.37% | 85.28% | 568.38% | - |
| Selling, General & Admin | 12.15M | 5.51M | 6.02M | 5.52M | 7.95M | 22.49M | 46.41M | 34.5M | 37.88M | 28.25M |
| SG&A % of Revenue | 57.8% | 55.81% | 45.84% | 55.91% | 54.75% | 28.46% | 37.84% | 77.74% | 559.6% | - |
| Research & Development | 575K | 431K | 398K | 332K | 633K | 520K | 652K | 1.42M | 594K | 168K |
| R&D % of Revenue | 2.74% | 4.37% | 3.03% | 3.36% | 4.36% | 0.66% | 0.53% | 3.19% | 8.77% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.93M | 0 | 527.5K |
| Operating Income | -2.66M▲ 0% | -3.99M▼ 50.2% | -1.63M▲ 59.0% | -3.24M▼ 98.2% | -3.97M▼ 22.7% | 9.8M▲ 346.7% | 23.59M▲ 140.7% | -21.61M▼ 191.6% | -38.63M▼ 78.7% | -26.89M▲ 0% |
| Operating Margin % | -12.64% | -40.44% | -12.45% | -32.8% | -27.37% | 12.4% | 19.24% | -48.7% | -570.59% | -2496.56% |
| Operating Income Growth % | 25.89% | -50.23% | 59.05% | -98.23% | -22.66% | 346.69% | 140.74% | -191.6% | -78.73% | - |
| EBITDA | -2.31M | -3.65M | -1.25M | -2.84M | -3.44M | 14.74M | 28.66M | -14.91M | -31.98M | -22.18M |
| EBITDA Margin % | -10.99% | -37.02% | -9.53% | -28.77% | -23.71% | 18.64% | 23.36% | -33.6% | -472.45% | -2059.33% |
| EBITDA Growth % | 28.23% | -58.21% | 65.75% | -127.1% | -21.15% | 528.12% | 94.46% | -152.05% | -114.45% | 19.19% |
| D&A (Non-Cash Add-back) | 347K | 337K | 383K | 398K | 531K | 4.93M | 5.06M | 6.7M | 6.64M | 4.71M |
| EBIT | -3.79M | -3.99M | -1.63M | -3.11M | -2.02M | 6.45M | 23.67M | -21.52M | -38.98M | -29.52M |
| Net Interest Income | -212K | 177K | 167K | 133K | -233K | -506K | -611K | -1.2M | -3.35M | -3.71M |
| Interest Income | 1K | 231K | 167K | 133K | 62K | 642K | 153K | 78K | 0 | 0 |
| Interest Expense | 213K | 54K | 0 | 0 | 295K | 1.15M | 764K | 1.27M | 3.35M | 3.71M |
| Other Income/Expense | -1.35M | 327K | 167K | 133K | 1.66M | -4.5M | -687K | -785K | -3.7M | -4.44M |
| Pretax Income | -2.87M▲ 0% | -3.66M▼ 27.7% | -1.47M▲ 60.0% | -3.11M▼ 111.7% | -2.31M▲ 25.5% | 5.3M▲ 329.3% | 22.91M▲ 331.8% | -22.4M▼ 197.8% | -42.33M▼ 89.0% | -31.33M▲ 0% |
| Pretax Margin % | -13.65% | -37.12% | -11.18% | -31.45% | -15.94% | 6.71% | 18.68% | -50.46% | -625.26% | -2909.1% |
| Income Tax | 212K | -17.99M | 103K | 0 | 12K | -968K | 4.45M | -6.02M | 7.2M | 15.18M |
| Effective Tax Rate % | -7.39% | 491.13% | -7.02% | 0% | -0.52% | -18.25% | 19.4% | 26.87% | -17% | -48.44% |
| Net Income | -2.87M▲ 0% | 41.83M▲ 1558.5% | -1.74M▼ 104.2% | -3.15M▼ 80.8% | -2.13M▲ 32.5% | 6.27M▲ 395.2% | 18.46M▲ 194.3% | -16.78M▼ 190.9% | -53.36M▼ 218.0% | -41.7M▲ 0% |
| Net Margin % | -13.65% | 423.95% | -13.26% | -31.86% | -14.64% | 7.94% | 15.05% | -37.81% | -788.24% | -3872.24% |
| Net Income Growth % | 20.33% | 1558.54% | -104.16% | -80.8% | 32.45% | 395.2% | 194.32% | -190.9% | -217.98% | -50.25% |
| Net Income (Continuing) | -4.01M | -2.24M | -1.57M | -3.11M | -2.33M | 6.27M | 18.46M | -16.38M | -49.52M | -46.51M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 201K | 0 | 0 | -402K | -3.84M | 1000K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.17▲ 0% | 2.59▲ 1623.5% | -0.15▼ 105.8% | -0.26▼ 73.3% | -0.20▲ 23.1% | 0.40▲ 300.0% | 1.02▲ 155.0% | -0.98▼ 196.1% | -2.61▼ 166.3% | -1.00▲ 0% |
| EPS Growth % | 22.73% | 1623.53% | -105.79% | -73.33% | 23.08% | 300% | 155% | -196.08% | -166.33% | -8.61% |
| EPS (Basic) | -0.17 | 2.61 | -0.15 | -0.26 | -0.20 | 0.41 | 1.17 | -0.98 | -2.61 | - |
| Diluted Shares Outstanding | 17.08M | 15.7M | 11.4M | 11.56M | 11.6M | 18.39M | 18.65M | 17.21M | 19.08M | 41.54M |
| Basic Shares Outstanding | 16.69M | 15.56M | 11.4M | 11.56M | 11.6M | 15.17M | 15.85M | 17.21M | 19.08M | 41.54M |
| Dividend Payout Ratio | - | - | - | - | - | 72.47% | 50.66% | - | - | - |
PRPH Balance Sheet
ProPhase Labs, Inc. (PRPH) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.63M | 28.92M | 18.24M | 9.95M | 15.89M | 61.32M | 60.83M | 47.59M | 30.64M | 7.77M |
| Cash & Short-Term Investments | 441K | 21.94M | 8.24M | 1.36M | 8.46M | 17.51M | 17.44M | 4.74M | 678K | 405K |
| Cash Only | 441K | 3.17M | 1.55M | 434K | 6.82M | 8.66M | 9.11M | 1.61M | 678K | 405K |
| Short-Term Investments | 0 | 18.77M | 6.69M | 926K | 1.64M | 8.86M | 8.33M | 3.13M | 0 | 0 |
| Accounts Receivable | 5.77M | 1.95M | 7.8M | 6.82M | 3.15M | 37.71M | 37.05M | 35.81M | 20.06M | 3.28M |
| Days Sales Outstanding | 100.22 | 71.95 | 216.84 | 252.13 | 79.34 | 174.13 | 110.27 | 294.52 | 1.08K | 5.39K |
| Inventory | 2.74M | 1.53M | 1.9M | 1.46M | 3.04M | 4.6M | 3.98M | 2.29M | 1.14M | 266K |
| Days Inventory Outstanding | 91.22 | 70.57 | 83.23 | 73.34 | 111.95 | 36.32 | 27.91 | 29.71 | 60.29 | -313.81 |
| Other Current Assets | 417K | 2.86M | 296K | 304K | 1.24M | 1.5M | 2.37M | 4.74M | 8.76M | 3.82M |
| Total Non-Current Assets | 3.17M | 5.24M | 2.5M | 2.33M | 15.52M | 27.98M | 26.81M | 44.34M | 32.56M | 57.93M |
| Property, Plant & Equipment | 3.17M | 2.74M | 2.5M | 2.33M | 8.31M | 10.35M | 11.35M | 14.9M | 11.62M | 2.35M |
| Fixed Asset Turnover | 6.62x | 3.60x | 5.25x | 4.24x | 1.75x | 7.64x | 10.81x | 2.98x | 0.58x | 0.15x |
| Goodwill | 0 | 0 | 0 | 0 | 901K | 5.71M | 5.71M | 5.23M | 5.23M | 3.97M |
| Intangible Assets | 0 | 0 | 0 | 0 | 1.23M | 10.85M | 8.47M | 12.33M | 9.75M | 7.81M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 2.75M | 0 | 0 | 0 | 0 | 44.14M |
| Other Non-Current Assets | 0 | 2.5M | 0 | 0 | 2.32M | 1.07M | 1.28M | 4.56M | 5.97M | 6.71M |
| Total Assets | 12.8M▲ 0% | 34.16M▲ 166.8% | 20.74M▼ 39.3% | 12.27M▼ 40.8% | 31.41M▲ 155.9% | 89.3M▲ 184.3% | 87.65M▼ 1.8% | 91.93M▲ 4.9% | 63.2M▼ 31.2% | 65.7M▲ 0% |
| Asset Turnover | 1.64x | 0.29x | 0.63x | 0.80x | 0.46x | 0.89x | 1.40x | 0.48x | 0.11x | 0.02x |
| Asset Growth % | -13.67% | 166.84% | -39.3% | -40.81% | 155.87% | 184.33% | -1.84% | 4.88% | -31.25% | -158.61% |
| Total Current Liabilities | 6.84M | 1.81M | 4.23M | 933K | 6.29M | 15.52M | 16.07M | 20.86M | 32.13M | 55.29M |
| Accounts Payable | 2.16M | 562K | 437K | 432K | 3.77M | 7.03M | 5.91M | 8.64M | 13.72M | 41.85M |
| Days Payables Outstanding | 71.88 | 25.9 | 19.11 | 21.72 | 138.92 | 55.47 | 41.45 | 112.1 | 723.51 | -7.78K |
| Short-Term Debt | 1.49M | 0 | 0 | 0 | 329K | 663K | 301K | 2.79M | 6.57M | 6.72M |
| Deferred Revenue (Current) | 0 | 0 | 206K | 104K | 169K | 2.03M | 2.5M | 2.38M | 1.7M | 6.09M |
| Other Current Liabilities | 3.02M | 1.25M | 3.2M | 310K | 1.52M | 3.92M | 2.93M | 2.6M | 8.03M | 5.05M |
| Current Ratio | 1.41x | 15.96x | 4.31x | 10.66x | 2.52x | 3.95x | 3.78x | 2.28x | 0.95x | 0.95x |
| Quick Ratio | 1.01x | 15.11x | 3.86x | 9.10x | 2.04x | 3.65x | 3.54x | 2.17x | 0.92x | 0.92x |
| Cash Conversion Cycle | 119.56 | 116.61 | 280.96 | 303.76 | 52.38 | 154.97 | 96.73 | 212.13 | 418.19 | 12.86K |
| Total Non-Current Liabilities | 0 | 0 | 0 | 110K | 14.55M | 15.14M | 7.94M | 21.69M | 23.71M | 3.55M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 9.99M | 10.04M | 2.4M | 7.33M | 11.65M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 4.4M | 4.2M | 4.26M | 8.33M | 6.35M | 15.57M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 224K | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.92M | 4.92M | 10.92M |
| Total Liabilities | 6.84M | 1.07M | 4.23M | 1.04M | 20.85M | 30.67M | 24.02M | 42.54M | 55.85M | 58.84M |
| Total Debt | 1.49M | 0 | 0 | 0 | 14.72M | 14.9M | 6.96M | 18.46M | 24.57M | 7.68M |
| Net Debt | 1.05M | -3.17M | -1.55M | -434K | 7.91M | 6.24M | -2.15M | 16.85M | 23.89M | 7.28M |
| Debt / Equity | 0.25x | - | - | - | 1.39x | 0.25x | 0.11x | 0.37x | 3.34x | 3.34x |
| Debt / EBITDA | - | - | - | - | - | 1.01x | 0.24x | - | - | -0.35x |
| Net Debt / EBITDA | - | - | - | - | - | 0.42x | -0.07x | - | - | -0.33x |
| Interest Coverage | -12.47x | -73.89x | - | - | -13.47x | 8.54x | 30.88x | -16.95x | -11.53x | -7.96x |
| Total Equity | 5.96M▲ 0% | 31.85M▲ 434.2% | 16.5M▼ 48.2% | 11.23M▼ 31.9% | 10.56M▼ 6.0% | 58.63M▲ 455.4% | 63.63M▲ 8.5% | 49.38M▼ 22.4% | 7.35M▼ 85.1% | 6.86M▲ 0% |
| Equity Growth % | -32.47% | 434.17% | -48.18% | -31.95% | -6.01% | 455.4% | 8.53% | -22.39% | -85.11% | -306.4% |
| Book Value per Share | 0.35 | 2.03 | 1.45 | 0.97 | 0.91 | 3.19 | 3.41 | 2.87 | 0.39 | 0.17 |
| Total Shareholders' Equity | 5.96M | 31.85M | 16.5M | 11.23M | 10.56M | 58.63M | 63.63M | 49.38M | 7.35M | 6.86M |
| Common Stock | 13K | 14K | 14K | 14K | 14K | 16K | 16K | 18K | 23K | 29K |
| Retained Earnings | -19.69M | 22.14M | 4.53M | -1.51M | -3.63M | 2.64M | 11.75M | -5.03M | -58.39M | -65.74M |
| Treasury Stock | -30.74M | -47.02M | -47.49M | -47.49M | -47.49M | -48.41M | -58.03M | -64M | -64M | -49.64M |
| Accumulated OCI | -5.13M | -78K | -24K | -2K | -11K | -175K | 757K | -300K | -198K | -198K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PRPH Cash Flow Statement
ProPhase Labs, Inc. (PRPH) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -472K | -2.84M | -2.12M | -841K | -2.59M | -13.62M | 28.55M | -11.35M | -17.54M | -17.54M |
| Operating CF Margin % | -2.25% | -28.76% | -16.14% | -8.52% | -17.86% | -17.23% | 23.28% | -25.57% | -259.05% | - |
| Operating CF Growth % | 86.5% | -501.27% | 25.33% | 60.31% | -208.2% | -425.42% | 309.64% | -139.75% | -54.55% | 810.72% |
| Net Income | -2.87M | 41.83M | -1.74M | -3.15M | -2.13M | 6.27M | 18.46M | -16.78M | -49.52M | -41.7M |
| Depreciation & Amortization | 426K | 337K | 383K | 398K | 458K | 3.56M | 5.06M | 6.7M | 6.64M | 5.19M |
| Stock-Based Compensation | 1K | 78K | 634K | 744K | 1.46M | 3.18M | 3.99M | 3.54M | 3.64M | 2.08M |
| Deferred Taxes | 0 | -17.99M | 130K | 12K | -1.89M | 557K | -138K | 0 | 7.15M | 0 |
| Other Non-Cash Items | 24K | -26.67M | 170K | 40K | 118K | -311K | 5.52M | 896K | -334K | -3.11M |
| Working Capital Changes | 1.95M | -421K | -1.7M | 1.11M | -608K | -26.88M | -4.34M | -5.7M | 14.89M | 19.37M |
| Change in Receivables | -1.77M | 3.83M | -1.02M | 936K | -1.04M | -30.47M | -4.5M | 718K | 4.74M | 56K |
| Change in Inventory | 1.59M | 1.21M | -372K | 444K | -1.47M | -1.75M | 702K | 135K | 1.36M | 948K |
| Change in Payables | 1.17M | -1.59M | -125K | -14K | 3.34M | 2.45M | -1.12M | 3.48M | 5.07M | -920K |
| Cash from Investing | -651K | 21.77M | 11.86M | 5.54M | -1.02M | -19.67M | -2.08M | -1.37M | 2.42M | -40K |
| Capital Expenditures | -651K | -208K | -140K | -228K | -1.69M | -4.23M | -3.92M | -3.15M | -906K | 0 |
| CapEx % of Revenue | 3.1% | 2.11% | 1.07% | 2.31% | 11.64% | 5.35% | 3.2% | 7.11% | 13.38% | - |
| Acquisitions | 0 | 40.83M | 140K | 228K | -2.5M | -9.07M | 452K | -2.9M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -651K | 40.83M | -139K | -228K | 3.89M | -700K | 0 | 524K | -46K | -40K |
| Cash from Financing | -100K | -16.2M | -11.36M | -5.82M | 9.99M | 35.13M | -26.02M | 5.76M | 14.19M | 9.66M |
| Debt Issued (Net) | -100K | -1.5M | 0 | 0 | 10M | -45K | -7.04M | 10.52M | 5.61M | 1.69M |
| Equity Issued (Net) | 0 | -1000K | 0 | 0 | 0 | 1000K | -1000K | -1000K | 1000K | 1.28M |
| Dividends Paid | 0 | 0 | -11.7M | -5.82M | 0 | -4.55M | -9.35M | 0 | 0 | 0 |
| Share Repurchases | 0 | -16.28M | 0 | 0 | 0 | -917K | -9.63M | -5.97M | 0 | -3.72M |
| Other Financing | 0 | 1.58M | 338K | 0 | -10K | 0 | -7.47M | 1.2M | 978K | 5M |
| Net Change in Cash | -1.22M▲ 0% | 2.73M▲ 323.4% | -1.62M▼ 159.3% | -1.12M▲ 30.8% | 6.38M▲ 669.8% | 1.84M▼ 71.1% | 451K▼ 75.5% | -6.96M▼ 1643.2% | -931K▲ 86.6% | -689K▲ 0% |
| Free Cash Flow | -1.12M▲ 0% | -3.05M▼ 171.2% | -2.26M▲ 25.8% | -1.07M▲ 52.7% | -4.28M▼ 300.5% | -17.85M▼ 317.0% | 24.63M▲ 238.0% | -14.5M▼ 158.9% | -18.44M▼ 27.2% | -22.75M▲ 0% |
| FCF Margin % | -5.34% | -30.87% | -17.21% | -10.82% | -29.5% | -22.58% | 20.08% | -32.68% | -272.44% | -2112.53% |
| FCF Growth % | 73.36% | -171.24% | 25.84% | 52.68% | -300.47% | -316.96% | 237.99% | -158.88% | -27.17% | -36.8% |
| FCF per Share | -0.07 | -0.19 | -0.20 | -0.09 | -0.37 | -0.97 | 1.32 | -0.84 | -0.97 | -0.97 |
| FCF Conversion (FCF/Net Income) | 0.16x | -0.07x | 1.22x | 0.27x | 1.22x | -2.17x | 1.55x | 0.68x | 0.33x | 0.55x |
| Interest Paid | 0 | 54K | 0 | 0 | 0 | 0 | 763K | 932K | 3.1M | 1.65M |
| Taxes Paid | 0 | 1.35M | 0 | 103K | 0 | 0 | 1.7M | 3M | 1.13M | -513K |
PRPH Key Ratios
ProPhase Labs, Inc. (PRPH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -38.78% | 221.28% | -7.2% | -22.69% | -19.51% | 18.13% | 30.2% | -29.7% | -188.11% | -607.84% |
| Return on Invested Capital (ROIC) | -25.47% | -16.77% | -5.62% | -18.87% | -20.37% | 17.64% | 28.01% | -25.38% | -59.44% | -59.44% |
| Gross Margin | 47.9% | 19.74% | 36.42% | 26.48% | 31.73% | 41.51% | 57.61% | 36.59% | -2.22% | 191.36% |
| Net Margin | -13.65% | 423.95% | -13.26% | -31.86% | -14.64% | 7.94% | 15.05% | -37.81% | -788.24% | -3872.24% |
| Debt / Equity | 0.25x | - | - | - | 1.39x | 0.25x | 0.11x | 0.37x | 3.34x | 3.34x |
| Interest Coverage | -12.47x | -73.89x | - | - | -13.47x | 8.54x | 30.88x | -16.95x | -11.53x | -7.96x |
| FCF Conversion | 0.16x | -0.07x | 1.22x | 0.27x | 1.22x | -2.17x | 1.55x | 0.68x | 0.33x | 0.55x |
| Revenue Growth | 1.99% | -53.05% | 33.03% | -24.76% | 46.96% | 444.59% | 55.17% | -63.81% | -84.75% | -91.55% |
PRPH SEC Filings & Documents
ProPhase Labs, Inc. (PRPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
PRPH Frequently Asked Questions
ProPhase Labs, Inc. (PRPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ProPhase Labs, Inc. (PRPH) reported $1.1M in revenue for fiscal year 2024. This represents a 35% increase from $0.8M in 1996.
ProPhase Labs, Inc. (PRPH) saw revenue decline by 84.7% over the past year.
ProPhase Labs, Inc. (PRPH) reported a net loss of $41.7M for fiscal year 2024.
Dividend & Returns
ProPhase Labs, Inc. (PRPH) has a return on equity (ROE) of -188.1%. Negative ROE indicates the company is unprofitable.
ProPhase Labs, Inc. (PRPH) had negative free cash flow of $22.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More PRPH
ProPhase Labs, Inc. (PRPH) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates